The effects of nocturnal acid breakthrough on Helicobacter pylori eradication

被引:25
作者
Kim, JI [1 ]
Park, SH [1 ]
Kim, JK [1 ]
Chung, IS [1 ]
Chung, KW [1 ]
Sun, HS [1 ]
机构
[1] Catholic Univ Korea, Dept Internal Med, Div Gastroenterol, Seoul, South Korea
关键词
Helicobacter pylori; nocturnal acid breakthrough (NAB); gastric pH;
D O I
10.1046/j.1523-5378.2002.00105.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background. The effects of nocturnal gastric acid breakthrough (NAB) on Helicobacter pylori eradication are still unknown in peptic ulcer patients. The purposes of this study were to compare the effect of lansoprazole 30 mg twice a day (bid) to lansoprazole 60 mg once a day (qd) on the prevalence of NAB, and to determine whether NAB affects the eradication of H. pylori in peptic ulcer patients. Methods. Experiments were carried out in 67 patients with H. pylori-positive peptic ulcers. They were randomized into two groups, one treated with a combination of lansoprazole 60 mg, clarithromycin 1.0 g , and amoxycillin 2.0 g once a day before breakfast (qd group), and the other, divided doses of the drugs were given before breakfast and dinner (bid group) for 2 weeks. Results. NAB occurred in 31 patients, 55.2% in qd group, and 39.5% in bid group (p=.226). H. pylori eradication was achieved in 61.3% in NAB positive group and 83.3% in NAB negative group (p=.055). The mean duration of NAB for H. pylori eradication group was 99.3+/-22.7 min, and 293.2+/-49.8 min for H. pylori persistence group (p<.05). The median intragastric pH of the H. pylori eradication and persistence group was 5.7+/-0.2 and 4.2+/-0.4, respectively (p<.05). Conclusions. Neither the morning dose and the divided dose regimen of lansoprazole affected the intragastric acidity and occurrence of the NAB. NAB did not influence H. pylori eradication in peptic ulcer patients, but the duration of NAB and total intragastric median pH were found to influence the H. pylori eradication.
引用
收藏
页码:331 / 336
页数:6
相关论文
共 18 条
[1]   CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole [J].
Adachi, K ;
Katsube, T ;
Kawamura, A ;
Takashima, T ;
Yuki, M ;
Amano, K ;
Ishihara, S ;
Fukuda, R ;
Watanabe, M ;
Kinoshita, Y .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (10) :1259-1266
[2]   Helicobacter pylori augments the acid inhibitory effect of omeprazole on parietal cells and gastric H+/K+-ATPase [J].
Beil, W ;
Sewing, KF ;
Busche, R ;
Wagner, S .
GUT, 2001, 48 (02) :157-162
[3]  
Chang CS, 1999, HEPATO-GASTROENTEROL, V46, P2713
[4]  
Dekkers CPM, 1999, ALIMENT PHARM THERAP, V13, P49
[5]   Morning versus evening dosing of lansoprazole 30 mg daily on twenty-four-hour intragastric acidity in healthy subjects [J].
Fraser, AG ;
Sawyerr, AM ;
Hudson, M ;
Smith, MSH ;
Pounder, RE .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 (04) :523-527
[6]  
Hatlebakk JG, 1998, ALIMENT PHARM THERAP, V12, P1235
[7]  
Katz PO, 1998, ALIMENT PHARM THER, V12, P1231
[8]   Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese [J].
Kinoshita, Y ;
Kawanami, C ;
Kishi, K ;
Nakata, H ;
Seino, Y ;
Chiba, T .
GUT, 1997, 41 (04) :452-458
[9]   INTRAGASTRIC ACIDITY AS A PREDICTOR OF THE SUCCESS OF HELICOBACTER-PYLORI ERADICATION - A STUDY IN PEPTIC-ULCER PATIENTS WITH OMEPRAZOLE AND AMOXICILLIN [J].
LABENZ, J ;
STOLTE, M ;
BLUM, AL ;
JORIAS, I ;
LEVERKUS, F ;
SOLLBOHMER, M ;
BERTRAMS, J ;
BORSCH, G .
GUT, 1995, 37 (01) :39-43
[10]  
Leite LP, 1996, AM J GASTROENTEROL, V91, P1527